Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.95 USD

67.95
1,162,193

-0.04 (-0.06%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $67.96 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment

by Zacks Equity Research

The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.

Zacks Equity Research

Walgreens (WBA) to Advance Diabetes Care at FFL Conference

by Zacks Equity Research

Walgreens (WBA) will sponsor Children with Diabetes' FFL event to make a difference in the lives of the 122 million individuals afflicted by diabetes and pre-diabetes.

Zacks Equity Research

Hologic (HOLX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Hologic (HOLX) closed the most recent trading day at $80.24, moving -0.72% from the previous trading session.

Zacks Equity Research

Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.

Zacks Equity Research

Amedisys (AMED) to Advance Value-Based Care With Optum Merger

by Zacks Equity Research

Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) backed by the acquisition of Oak Street Health, which broadens its value-based primary care platform.

Zacks Equity Research

Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Stock

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Zacks Equity Research

McKesson's (MCK) Latest Launch to Give Access to OTC Products

by Zacks Equity Research

McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.

Zacks Equity Research

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

by Zacks Equity Research

Masimo's (MASI) solid product suite raises optimism about the stock.

Zacks Equity Research

Dexcom (DXCM) to Launch New Product in 2024, Ups Long-Term View

by Zacks Equity Research

Dexcom (DXCM) announces encouraging developments in 2024, including faster coverage for its products by private payers and new product launch for diabetic patients not on insulin.

Zacks Equity Research

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.

Zacks Equity Research

Inspire Medical (INSP) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Inspire Medical's (INSP) global presence.

Zacks Equity Research

Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients

by Zacks Equity Research

Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.

Zacks Equity Research

Envista (NVST) Gains From New Acquisitions Amid FX Woes

by Zacks Equity Research

Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.

Zacks Equity Research

Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.

Zacks Equity Research

Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.

Zacks Equity Research

Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure

by Zacks Equity Research

Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.

Zacks Equity Research

Hologic (HOLX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Hologic (HOLX) closed at $81.49 in the latest trading session, marking a +0.07% move from the prior day.

Zacks Equity Research

Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio

by Zacks Equity Research

Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.

Zacks Equity Research

Masimo's (MASI) Launch to Serve the Personalized Hearables Market

by Zacks Equity Research

Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.

Zacks Equity Research

QIAGEN's (QGEN) ForenSeq MainstAY Workflow Gets FBI Nod

by Zacks Equity Research

QIAGEN's (QGEN) ForenSeq MainstAY workflow is a cost-effective substitute for analyzing short tandem repeats with capillary electrophoresis and facilitates volume casework for sexual assault cases.

Zacks Equity Research

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Zacks Equity Research

Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering

by Zacks Equity Research

Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.